AngioDynamics

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. The company was founded by Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

AngioDynamics reports robust Q2 growth driven by key products

AngioDynamics delivered strong financial results driven by key product growth, reaffirming confidence in guidance and market stability.
Strategic focus on innovation, clinical trials, and global expansion positions the company for long-term success and market leadership.
Challenges in certain business segments require attention, but opportunities in new product releases and market expansion offer growth potential.
Overall, AngioDynamics remains committed to platform technologies and being a trusted care delivery partner, ensuring a strong strategic position in the market.

AngioDynamics reports Q3 growth, navigates challenges, eyes new opportunities

AngioDynamics showed solid revenue growth in Q3 2023, led by the Med Tech segment despite challenges with AngioVac.
The company is focused on addressing sales declines, exploring new product potentials, and maintaining cash flow neutrality.
Opportunities lie in new product usage trends, potential market expansions, and commitment to growth and profitability globally.
Despite revised guidance, AngioDynamics remains resilient in navigating challenges and pursuing strategic opportunities for future growth.

AngioDynamics posts solid earnings, eyes growth through innovation and markets

AngioDynamics delivered strong financial performance in Q4 2023 and FY '23, driven by growth in key segments and international markets.
The company's strategic focus on core businesses and favorable legal outcomes position it for future growth.
Challenges include projected losses for FY '24 and the need to boost Med Device revenue growth.
Opportunities lie in product innovation, clinical study outcomes, and market expansion initiatives.

AngioDynamics reports Q1 growth, eyes innovation amid investor concerns

AngioDynamics' Q1 performance reflects mixed results with revenue growth but losses per share, driven by strong segments like NanoKnife.
The company's financial position remains stable with healthy cash reserves and a positive outlook for future cash flow and revenue growth.
Challenges lie in balancing declining segments like mechanical thrombectomy with growth opportunities in new treatment areas and investor relations.
Opportunities for growth exist through innovation in the Auryon platform, potential indications from the APEX PE study, and strategic investor engagement.
AngioDynamics navigates a complex landscape of growth and challenges, focusing on innovation and financial stability amidst investor concerns.

AngioDynamics reports Q2 growth, navigates challenges with strategic initiatives

AngioDynamics delivered steady revenue growth in Q2 2024, driven by international expansion and strong performance in key segments.
While facing challenges in certain businesses, the company is strategically restructuring operations and investing in innovation for future growth.
Opportunities lie in expanding Auryon's market reach, optimizing manufacturing processes, and maintaining a focus on cost efficiency.
Overall, AngioDynamics is navigating challenges while positioning itself for long-term success through strategic initiatives and product enhancements.

AngioDynamics reports strong Q3 growth, eyes global expansion opportunities

AngioDynamics demonstrated solid revenue growth and strategic milestones in Q3 2024, with a focus on product innovation and international expansion.
While facing challenges in certain business segments, the company's regulatory successes and financial stability position it well for future growth.
Opportunities in upcoming data releases and market trends present avenues for AngioDynamics to capitalize on its strengths and drive further success.

AngioDynamics reports Q4 growth, eyes revenue expansion in 2025

AngioDynamics delivered a mixed performance in Q4 2024 with growth in Med Tech segment but declines in mechanical thrombectomy and Med Device segments.
Despite challenges, the company managed to generate excess cash flow and narrow its adjusted EBITDA loss, showcasing financial resilience.
Future opportunities lie in revenue growth projections for fiscal year 2025 and strategic initiatives aimed at market expansion and optimization.

AngioDynamics reports modest revenue growth and progresses towards profitability

AngioDynamics demonstrated overall growth in revenue and progress towards profitability in Q1 2025. While facing challenges with NanoKnife revenue and profitability, the company's Med Tech segment showed strength with Auryon and AlphaVac. Opportunities lie in cost savings from outsourced manufacturing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. It operates through the Med Tech and Med Device segments. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

AngioDynamics (ANGO) Down 8.9% Since Last Earnings Report: Can It Rebound?

AngioDynamics Inc (NASDAQ:ANGO) files its latest 10-K with SEC for the fiscal year ended on May 31, 2019.

AngioDynamics Inc (ANGO) Files 10-K for the Fiscal Year Ended on May 31, 2019

AngioDyamics (ANGO) gains from solid segmental contributions in fourth-quarter fiscal 2019.

AngioDynamics (ANGO) Q4 Earnings Miss, Revenues Top Estimates

AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q4 2019 Results - Earnings Call Transcript

AngioDynamics unveils its next round of earnings this Wednesday, July 10.

Q4 Earnings Outlook For AngioDynamics

Intra-Cellular Therapies

Biotech stocks saw muted sentiment in the holiday-shortened week ending July 5 after a strong rebound in the later part of the previous week.

The Week Ahead In Biotech: Conferences, Clinical Trial Readouts And Earnings

The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt.

AngioDynamics Divests NAMIC Portfolio to Medline Industries

AngioDynamics' (ANGO) pilot study is intended to support the approval of a future PMA in the United States.

AngioDynamics IDE Application for NanoKnife Gets FDA Nod

Ensign Group

Genomic Health

Ionis Pharma

Masimo

National Research Corp

Osiris Therapeutics

These healthcare stocks will help you not only profit from the growing demand, but also the growing tech in the healthcare sector.

7 A-Rated Healthcare Stocks for Industry Expansion

Why Is AngioDynamics (ANGO) Down 12.1% Since Last Earnings Report?

AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q3 2019 Results - Earnings Call Transcript

AngioDynamics delivered earnings and revenue surprises of -13.64% and -2.44%, respectively, for the quarter ended February 2019. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics Lags Q3 Earnings and Revenue Estimates

AngioDynamics, Inc. recently announced that the FDA has granted an expanded 510(k) clearance for its OARtrac Radiation Dose Monitoring System for use during cancer treatments.

AngioDynamics' Latest FDA Approval to Boost Oncology Unit

News for AngioDynamics Stock (ANGO)